Oppenheimer raised the price target for the ShockWave Medical Inc. (NASDAQ:SWAV) stock from “a Perform” to “an Underperform”. The rating was released on September 06, 2022, according to finviz. The research report from BofA Securities has resumed the stock to Buy, with a price target set at $200. The stock was upgraded by Wells Fargo, who disclosed in a research note on December 06, 2021, from Equal Weight to Overweight and set the price objective to $235. In their research brief published July 15, 2021, SVB Leerink analysts initiated the ShockWave Medical Inc. stock to Outperform with a price target of $208.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of ShockWave Medical Inc. (NASDAQ:SWAV) raised 4.70% to close Wednesday’s market session at $264.06, higher as compared to yesterday’s close. The stock price fluctuated between $250.6874 and $268.31 throughout the trading session with the volume trading being 458580 shares, which represented a significant variation when compared to the three months average volume of 487.07K shares. The firm’s stock price fluctuated 4.94% within the last five trades and -10.58% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 58.33% in the last 6 months and -14.96% was subtracted to its value over the previous 3 months. SWAV stock is trading at a margin of -0.77%, -2.69% and 21.49% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.
Click here to get your free copy of the report
As of the close of trading, SWAV deals in the Healthcare domain. The stock is trading -17.62 percent below its 52-week high and 132.94 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 33.8. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does ShockWave Medical Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at 22.20 percent and the profit margin is 20.50 percent, and the company has reported a gross margin of 86.00 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $9.48 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio for ShockWave Medical Inc. (NASDAQ:SWAV) is 112.22. The price-to-earnings ratio is a method of assessing corporate values by comparing them to their per-share profit. Forward P/E stands at 70.85. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 22.04 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 26.70, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 1.60 percent of ShockWave Medical Inc. shares are owned by insiders, and 92.50 percent are held by financial institutions. PUCKETT DAN, the Chief Financial Officer at ShockWave Medical Inc. (SWAV) has sold 1,100 shares of firm on Nov 21 at a price of $246.96 against the total amount of $0.27 million. In another inside trade, WATKINS FRANK T, Director of ShockWave Medical Inc. (NASDAQ:SWAV) sold 3,000 shares of the firm on Nov 17 for a total worth of $0.73 million at a price of $244.44. An inside trade which took place on Nov 14, President & CEO of ShockWave Medical Inc. Godshall Douglas Evan sold 30,000 shares of firm against total price of $7.22 million at the cost of $240.81 per share.